Kronauge JF - Search Results

1

Preclinical evaluation of an 131I-labeled benzamide for targeted radiotherapy of metastatic melanoma.

Joyal JL, Barrett JA, Marquis JC, Chen J, Hillier SM, Maresca KP, Boyd M, Gage K, Nimmagadda S, Kronauge JF, Friebe M, Dinkelborg L, Stubbs JB, Stabin MG, Mairs R, Pomper MG, Babich JW. Joyal JL, et al. Among authors: kronauge jf. Cancer Res. 2010 May 15;70(10):4045-53. doi: 10.1158/0008-5472.CAN-09-4414. Epub 2010 May 4. Cancer Res. 2010. PMID: 20442292 Free PMC article.

2

Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution.

Barrett JA, Joyal JL, Hillier SM, Maresca KP, Femia FJ, Kronauge JF, Boyd M, Mairs RJ, Babich JW. Barrett JA, et al. Among authors: kronauge jf. Cancer Biother Radiopharm. 2010 Jun;25(3):299-308. doi: 10.1089/cbr.2009.0695. Cancer Biother Radiopharm. 2010. PMID: 20578835 Free article.

3

Phase-1 clinical trial results of high-specific-activity carrier-free 123I-iobenguane.

Chin BB, Kronauge JF, Femia FJ, Chen J, Maresca KP, Hillier S, Petry NA, James OG, Oldan JD, Armor T, Stubbs JB, Stabin MG, Babich JW. Chin BB, et al. Among authors: kronauge jf. J Nucl Med. 2014 May;55(5):765-71. doi: 10.2967/jnumed.113.124057. Epub 2014 Mar 13. J Nucl Med. 2014. PMID: 24627436 Free article. Clinical Trial.

4

Characterization of P-glycoprotein transport and inhibition in vivo.

Barbarics E, Kronauge JF, Cohen D, Davison A, Jones AG, Croop JM. Barbarics E, et al. Among authors: kronauge jf. Cancer Res. 1998 Jan 15;58(2):276-82. Cancer Res. 1998. PMID: 9443405

5

Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex.

Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Piwnica-Worms D, et al. Among authors: kronauge jf. Cancer Res. 1993 Mar 1;53(5):977-84. Cancer Res. 1993. PMID: 8094997

6

Interspecies variation in biodistribution of technetium (2-carbomethoxy-2-isocyanopropane)6+.

Kronauge JF, Noska MA, Davison A, Holman BL, Jones AG. Kronauge JF, et al. J Nucl Med. 1992 Jul;33(7):1357-65. J Nucl Med. 1992. PMID: 1613578 Free article.

7

The utilization of technetium-99m CPI as a myocardial perfusion imaging agent in exercise studies.

Sia ST, Holman BL, Campbell S, Lister-James J, English RJ, Kronauge JF, Davison A, Jones AG. Sia ST, et al. Among authors: kronauge jf. Clin Nucl Med. 1987 Sep;12(9):681-7. doi: 10.1097/00003072-198709000-00001. Clin Nucl Med. 1987. PMID: 3665310

8

Human pharmacokinetics and radiopharmacological studies of the myocardial perfusion agent: technetium (2-carbomethoxy-2-isocyano-propane)6+.

Kronauge JF, Leòn AS, Verdera ES, Balter HS, Leòn ET, Mut F, Oliveira MC, Garcia FA, Holman BL, Davison A, et al. Kronauge JF, et al. J Nucl Med. 1992 Nov;33(11):1949-57. J Nucl Med. 1992. PMID: 1432155 Free article.

9

Myocardial imaging with technetium-99m CPI: initial experience in the human.

Holman BL, Sporn V, Jones AG, Sia ST, Perez-Balino N, Davison A, Lister-James J, Kronauge JF, Mitta AE, Camin LL, et al. Holman BL, et al. Among authors: kronauge jf. J Nucl Med. 1987 Jan;28(1):13-8. J Nucl Med. 1987. PMID: 3794805 Free article.

10

Radiopharmacological evaluation in dogs of a new renal function agent.

Verdera S, Lòpez JJ, Tagle R, Garcia F, Fernandez G, Keuchkerian M, Heuguerot C, Jones AG, Kronauge JF. Verdera S, et al. Among authors: kronauge jf. J Nucl Biol Med (1991). 1994 Dec;38(4 Suppl 1):79-85. J Nucl Biol Med (1991). 1994. PMID: 7632773

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

40 results

Search Page

Filters